Alnylam Pharmaceuticals
ALNY
#567
Rank
ยฃ31.39 B
Marketcap
ยฃ236.71
Share price
-1.20%
Change (1 day)
26.58%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): ยฃ0.05839

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is ยฃ0.06797. In 2023 the company made an earnings per share (EPS) of -ยฃ2.67 an increase over its 2022 EPS that were of -ยฃ7.02.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)ยฃ0.05839
2023-ยฃ2.67-62%
2022-ยฃ7.0229.03%
2021-ยฃ5.44-3.36%
2020-ยฃ5.63-8.48%
2019-ยฃ6.157.67%
2018-ยฃ5.7139.74%
2017-ยฃ4.0912.94%
2016-ยฃ3.6238.84%
2015-ยฃ2.61-32.88%
2014-ยฃ3.88259.44%
2013-ยฃ1.08-31.25%
2012-ยฃ1.57

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
ยฃ5.56 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ1.56 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ32.57 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ2.07-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ0.55-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.18-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ0.94 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-ยฃ0.94-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA